Fecal Microbiota Transplantation in Dogs: Current Evidence

Research Summaries · 10 min read

✓ Our Veterinary Editorial Board — July 30, 2026

Fecal microbiota transplantation — the transfer of a processed fecal preparation from a healthy donor into a recipient’s gastrointestinal tract — is among the most direct expressions of the microbiome-as-therapeutic-target idea. Where dysbiosis is the problem, the reasoning goes, replacing the disrupted community with a healthy one might be the solution. In human medicine, FMT is established for recurrent Clostridioides difficile infection. In dogs, the evidence is younger, more heterogeneous, and more cautious — but genuinely promising in specific indications. This review examines the rationale, the canine evidence by condition, and the substantial questions that remain.

• Fecal microbiota transplantation (FMT) aims to restore a disrupted microbiome by transferring a screened, healthy donor’s community — a logical intervention for dysbiosis-driven disease.
• Canine evidence is strongest in acute settings: FMT has shown benefit in puppies with parvovirus and is under active study in acute hemorrhagic diarrhea syndrome (PMID: 29460302; PMID: 39094622).
• Evidence in chronic IBD is more preliminary, with case series and early studies suggesting potential but not yet establishing standard-of-care status (PMID: 33996366).
• Donor screening, standardization, and long-term safety remain the field’s central unresolved challenges.

The Rationale: Resetting the Community

The logic of FMT follows directly from what we know about dysbiosis. If chronic or acute gastrointestinal disease is accompanied by a perturbed microbial community — reduced diversity, loss of beneficial taxa, expansion of opportunists — then reintroducing a complete, diverse, healthy community could, in principle, restore colonization resistance, re-establish normal fermentation, and resolve the inflammatory milieu. A comprehensive review of FMT in dogs frames this rationale and the practical considerations (Pereira et al., 2021; PMID: 33131919), and a 2025 synthesis of the impact of FMT in dogs updates the state of the evidence (Sato et al., 2025; PMID: 40666732).

It’s important to be precise about what FMT is and isn’t. It’s not a probiotic — it’s not a defined set of organisms, but an entire community, with all the complexity and variability that implies. It’s not a postbiotic — it transfers living organisms intended to engraft, not inactivated components. This living, undefined, engrafting character is both its power and the source of its principal risks and standardization challenges.

Evidence by Indication

Canine parvovirus

Some of the most encouraging canine data come from an acute, high-mortality setting. A study of puppies with canine parvovirus infection reported that fecal microbiota transplantation was associated with faster resolution of clinical signs and improved outcomes compared with standard care alone (Pereira et al., 2018; PMID: 29460302). Parvovirus causes profound intestinal epithelial damage and secondary dysbiosis, and the rationale for microbiome restoration in this context is strong. This remains one of the more compelling canine FMT findings, though it derives from a relatively small evidence base.

Acute hemorrhagic diarrhea syndrome

Acute hemorrhagic diarrhea syndrome (AHDS) is another acute enteropathy marked by severe dysbiosis. A 2024 study compared treatment effects in dogs with AHDS, including fecal microbiota transplantation, contributing to the growing body of work on microbiome-restoring therapy in acute canine diarrhea (Busch et al., 2024; PMID: 39094622). The acute setting is attractive for FMT because the dysbiosis is pronounced, the natural history is often self-limiting, and the potential to accelerate recovery is clinically meaningful.

Inflammatory bowel disease

The chronic setting is harder. A report of FMT as a treatment for canine inflammatory bowel disease described clinical and microbiological responses, positioning FMT as a potential new therapeutic option for refractory cases (Niina et al., 2021; PMID: 33996366). The evidence here’s more preliminary — largely case reports and small series — and FMT isn’t established as standard of care for canine IBD. It remains an area of active investigation rather than settled practice, and it sits alongside dietary and nutritional approaches that are better supported for chronic enteropathy, which we review in our guide to IBD versus food sensitivity.

Donor Screening and Standardization: The Hard Part

The central challenges of FMT aren’t conceptual but operational. A donor must be rigorously screened — for enteric pathogens, parasites, antimicrobial-resistant organisms, and ideally for broader health status — because the procedure transfers an undefined living community with all its contents. Preparation methods (fresh versus frozen, delivery by enema, endoscopy, or oral capsule, dose and repeat schedule) vary between studies, making direct comparison difficult. And because FMT transfers a complex, living ecosystem, the long-term consequences of engraftment aren’t fully characterized. These are solvable problems, but they’re the reason FMT remains an investigational rather than a routine intervention in veterinary medicine.

FMT in Context: Not the Only Microbiome Tool

It’s useful to situate FMT within the broader toolkit of microbiome-directed therapies. For many patients, less invasive interventions — dietary modification, prebiotics, defined probiotics, or postbiotics — are appropriate first-line measures with far lower complexity and risk. FMT is most rationally reserved for situations where the dysbiosis is severe and the clinical stakes are high: acute, life-threatening enteropathies like parvovirus, or chronic cases refractory to conventional management. The dysbiosis that FMT targets is the same perturbation measured by the tools in our dysbiosis diagnostic framework; FMT is the most aggressive way to address it, and should be matched to the severity of the problem.

Limitations and Unresolved Questions

The honest summary is that canine FMT is promising but immature. The evidence base consists largely of small studies, case series, and reports; large randomized controlled trials are lacking. Optimal donors, preparations, dosing, and delivery routes aren’t standardized. Long-term safety data are sparse. Regulatory and quality-control frameworks for veterinary FMT preparations are still developing. None of this negates the genuine signals — particularly in parvovirus and acute diarrhea — but it argues for FMT to be practiced within a research or specialist context, with informed consent and appropriate monitoring, rather than as a casual clinic-side intervention.

Practical Protocol Elements

Where FMT is undertaken, the details of execution determine both safety and interpretability. A defensible protocol addresses several elements explicitly. Donor selection should favor a healthy, lean, regularly dewormed dog with no recent antibiotic exposure and a documented vaccination status, screened by fecal PCR and culture for enteric pathogens (including Salmonella, Campylobacter, and Clostridioides difficile) and parasites, and ideally assessed for broader health. Preparation may be fresh or frozen; freezing enables screening-before-use and banking but may affect community viability. Delivery routes include retention enema, endoscopic or colonoscopic administration, and oral capsules, each with different reach, retention, and sedation requirements. Dosing and the decision to repeat aren’t standardized and remain empirical.

Crucially, a protocol should specify how response will be measured. If dysbiosis is the target, then documenting the pre- and post-transplant community — for example, with the quantitative tools described in our dysbiosis diagnostic framework — transforms FMT from an empirical act into a measurable intervention. Without such measurement, it’s impossible to know whether engraftment occurred or whether clinical improvement (or its absence) can be attributed to the transplant. The maturity of FMT as a therapy depends on this kind of rigor becoming routine rather than exceptional (PMID: 33131919).

Owner Expectations and Informed Consent

FMT carries a particular communication burden because it’s at once intuitively appealing and genuinely uncertain. Owners who have heard of FMT’s success in human C. difficile infection may expect comparable, predictable results in dogs — and the gap between that expectation and the current canine evidence must be closed with honest consent. The appropriate framing is that FMT is a promising but investigational intervention: biologically rational, supported by encouraging signals in acute settings such as parvovirus (PMID: 29460302), but not yet standardized or proven across indications, and carrying unknown long-term consequences from transferring an undefined living community.

Informed consent for FMT should therefore cover the evidence status for the specific indication, the screening performed on the donor, the realistic probability of benefit versus the possibility of no effect or transient worsening, and the plan for monitoring and for alternative management if FMT doesn’t help. Positioning FMT accurately — as a specialist or research-context tool for selected, often severe cases rather than a casual clinic-side remedy — protects both the patient and the integrity of the field. The enthusiasm FMT generates is warranted by the biology; the restraint its evidence demands is warranted by the data.

The Comparative Context

It’s instructive to contrast the state of veterinary FMT with the human one, where FMT is an established, guideline-supported therapy for recurrent Clostridioides difficile infection and is regulated through standardized, screened preparations (including FDA-approved products). Veterinary medicine lacks equivalent standardization, regulatory clarity, and the depth of randomized evidence — which is precisely why canine FMT remains investigational rather than routine. The human experience also offers a cautionary lesson: early, enthusiastic adoption outpaced safety infrastructure, and serious adverse events from inadequately screened preparations eventually prompted tighter controls. Veterinary FMT can learn from this trajectory, building screening, standardization, and surveillance into the practice from the outset rather than retrofitting them after harm. The promise is real; the discipline required to realize it safely is the defining task of the field’s next phase (PMID: 40666732).

The Bottom Line

Fecal microbiota transplantation is the most direct attempt to correct dysbiosis by replacing the community wholesale, and the canine evidence supports genuine promise — strongest in acute, high-stakes settings like parvovirus and acute hemorrhagic diarrhea, more preliminary in chronic IBD. The field’s limiting factors are operational: donor screening, standardization, engraftment verification, and long-term safety. FMT belongs in the veterinary microbiome toolkit, but for now it belongs primarily in the hands of specialists and researchers, deployed where the severity of dysbiosis and the clinical stakes justify its complexity and uncertainty.

References

1. Pereira GQ, et al., “Fecal Microbiota Transplantation in Dogs,” Vet Clin North Am Small Anim Pract, 2021. PubMed 33131919
2. Sato R, et al., “Impact of fecal microbiota transplantation in dogs,” Front Vet Sci, 2025. PubMed 40666732
3. Pereira GQ, et al., “Fecal microbiota transplantation in puppies with canine parvovirus infection,” J Vet Intern Med, 2018. PubMed 29460302
4. Busch K, et al., “Comparing treatment effects on dogs with acute hemorrhagic diarrhea syndrome: fecal microbiota transplantation,” J Am Vet Med Assoc, 2024. PubMed 39094622
5. Niina A, et al., “Fecal microbiota transplantation as a new treatment for canine inflammatory bowel disease,” Biosci Microbiota Food Health, 2021. PubMed 33996366
6. AlShawaqfeh MK, Welter B, et al., “A dysbiosis index to assess microbial changes in fecal samples of dogs with chronic inflammatory enteropathy,” FEMS Microbiol Ecol, 2017. PubMed 29040443

Medical disclaimer: This article is for informational and educational purposes only and isn’t a substitute for professional veterinary advice, diagnosis, or treatment. Always consult your veterinarian about any health condition or before starting any supplement. Statements about supplements haven’t been evaluated by the FDA, and no product discussed is intended to diagnose, treat, cure, or prevent any disease. Read our full medical disclaimer.